Retatrutide vs Semaglutide

Retatrutide is an experimental triple-receptor drug (GIP, GLP-1, and glucagon) that has not yet been approved by the FDA for any use. Semaglutide, already FDA-approved, is a GLP-1-only drug sold under brand names like Ozempic, Wegovy, and Rybelsus for treating type 2 diabetes, obesity, chronic kidney disease, and reducing cardiovascular risk.

AI summary of the sources below.